[
Aged
Antigens, Surface
/ metabolism
Edetic Acid
/ analogs & derivatives
Gallium Isotopes
Gallium Radioisotopes
Glutamate Carboxypeptidase II
/ metabolism
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ diagnostic imaging
Oligopeptides
/ chemistry
Positron-Emission Tomography
/ methods
Prostatic Neoplasms
/ diagnostic imaging
Radiometry
Radiopharmaceuticals
/ chemistry
Tissue Distribution
Biochemical recurrence of prostate cancer
Dosimetry
PSMA-targeted PET
Prostate cancer imaging
[68Ga]Ga-P16-093
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
21
8
2019
medline:
3
6
2021
entrez:
21
8
2019
Statut:
ppublish
Résumé
This study was undertaken to evaluate radiation dosimetry for the prostate-specific membrane antigen targeted [ Under IND 133,222 and an IRB-approved research protocol, we evaluated the biodistribution and pharmacokinetics of [ [ [
Identifiants
pubmed: 31429050
doi: 10.1007/s11307-019-01421-7
pii: 10.1007/s11307-019-01421-7
pmc: PMC7028523
mid: NIHMS1537810
doi:
Substances chimiques
Antigens, Surface
0
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
Radiopharmaceuticals
0
gallium 68 PSMA-11
0
Edetic Acid
9G34HU7RV0
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
752-763Subventions
Organisme : NCI NIH HHS
ID : R43 CA217425
Pays : United States
Organisme : NCI NIH HHS
ID : R44 CA233140
Pays : United States
Références
Zha Z, Ploessl K, Choi SR, Wu Z, Zhu L, Kung HF (2018) Synthesis and evaluation of a novel urea-based
doi: 10.1016/j.nucmedbio.2017.12.007
Kung HF, Ploessl K, Choi SR, et al. (2017) Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy. U.S. Patent Application Publication, Pub. No. US 2017/0189568 A1, Jul 6, 2017. ( http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20170189568.PGNR.&OS=DN/20170189568&RS=DN/20170189568 )
Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, Hennrich U, Eisenhut M, Afshar-Oromieh A, Haberkorn U, Kopka K (2014) Novel preclinical and radiopharmaceutical aspects of [
doi: 10.3390/ph7070779
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U (2015) The diagnostic value of PET/CT imaging with the
doi: 10.1007/s00259-014-2949-6
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kubler H, Haberhorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M (2015) Evaluation of hybrid
doi: 10.2967/jnumed.115.154153
Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schäfer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U (2017) Diagnostic performance of
doi: 10.1007/s00259-017-3711-7
Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K (2017)
doi: 10.1007/s00259-017-3670-z
Maurer T, Eiber M, Schwaiger M, Gschwend J (2016) Current use of PSMA–PET in prostate cancer management. Nat Rev Urol 13:226–235
doi: 10.1038/nrurol.2016.26
Lenzo NP, Meyrick D, Turner JH (2018) Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer. Diagnostics 8:16–33
doi: 10.3390/diagnostics8010016
Bluemel C, Linke F, Herrmann K, Simunovic I, Eiber M, Kestler C, Buck AK, Schirbel A, Bley TA, Wester HJ, Vergho D, Becker A (2016) Impact of
doi: 10.1186/s13550-016-0233-4
Han S, Woo S, Kim YJ, Suh CH (2018) Impact of
doi: 10.1016/j.eururo.2018.03.030
Mathias CJ, Sun Y, Welch MJ et al (1988) Targeting radiopharmaceuticals: comparative biodistribution studies of gallium and indium complexes of multidentate ligands. Nucl Med Biol 15:69–81
Mathias CJ, Sun Y, Welch MJ, Connett JM, Philpott GW, Martell AE (1990) N,N’-Bis(2-hydroxybenzyl)-1-(4-bromoacetamidobenzyl)-1,2-ethylene- diamine-N,N'-diacetic acid: a new bifunctional chelate for radiolabeling antibodies. Bioconjug Chem 1:204–211,
doi: 10.1021/bc00003a005
Zöller M, Schuhmacher J, Reed J et al (1992) Establishment and characterization of monoclonal antibodies against an octahedral gallium chelate suitable for immunoscintigraphy with PET. J Nucl Med 33:1366–1372
pubmed: 1613579
Alexoff D, Kim D, Kung H (2018) Radiopharmaceutical labeling device. U.S. Patent Application Publication, Pub. No. US 2018/0250649 A1, Sep 6, 2018. ( http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20180250649.PGNR.&OS=DN/20180250649&RS=DN/20180250649 )
Green MA, Eitel JA, Fletcher JW et al (2016) Estimation of radiation dosimetry for
doi: 10.1016/j.nucmedbio.2016.11.002
Green MA, Mathias CJ, Fletcher JW (2016) Experience in production of
doi: 10.1016/j.apradiso.2016.07.010
Zankl M (2010) Adult male and female reference computational phantoms (ICRP Publication 110). Jpn J Health Phys 45:357–369
doi: 10.5453/jhps.45.357
Andersson M, Johansson L, Eckerman K, Mattsson S (2017) IDAC-dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res 7:88–98
doi: 10.1186/s13550-017-0339-3
Rischpler C, Beck TI, Okamoto S, Schlitter AM, Knorr K, Schwaiger M, Gschwend J, Maurer T, Meyer PT, Eiber M (2018)
doi: 10.2967/jnumed.117.204677
Braat A, van Nierop B, de Jong H et al (2017) The effect of
Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, Nilica B, Maffey-Steffan J, di Santo G, Bektic J, Horninger W, Virgolini IJ (2017) Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. Eur J Nucl Med Mol Imaging 44:1647–1655
doi: 10.1007/s00259-017-3743-z
Afshar-Oromich A, Hetzheim H, Kübler W et al (2016) Radiation dosimetry of
doi: 10.1007/s00259-016-3419-0
Pfob PH, Ziegler S, Graner FP et al (2016) Biodistribution and radiation dosimetry of
doi: 10.1007/s00259-016-3424-3
Demirci E, Toklu T, Yeyin N, Ocak M, Alan-Selcuk N, Araman A, Kabasakal L (2018) Estimation of the organ adsorbed doses and effective dose from
doi: 10.1093/rpd/ncy111
Sandgren K, Johansson L, Axelsson J, Jonsson J, Ögren M, Ögren M, Andersson M, Strandberg S, Nyholm T, Riklund K, Widmark A (2019) Radiation dosimetry of [
doi: 10.1186/s40658-018-0239-2
ICRP Publication 106 (2008) Radiation dose to patients from radiopharmaceuticals. Annals of the ICRP 38, Nos 1–2, 2008
Stabin MG (2008) Uncertainties in internal dose calculations for radiopharmaceuticals. J Nucl Med 49:853–860
doi: 10.2967/jnumed.107.048132
Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, Eze C, Rogowski P, Li M, Bartenstein P, Ganswindt U, Belka C (2018) Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiat Oncol 13:37–46
doi: 10.1186/s13014-018-0983-4
Zschaeck S, Lohaus F, Beck M, Habl G, Kroeze S, Zamboglou C, Koerber SA, Debus J, Hölscher T, Wust P, Ganswindt U, Baur ADJ, Zöphel K, Cihoric N, Guckenberger M, Combs SE, Grosu AL, Ghadjar P, Belka C (2018) PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiat Oncol 13:90–99
doi: 10.1186/s13014-018-1047-5
Koerber SA, Will L, Kratochwil C, Haefner MF, Rathke H, Kremer C, Merkle J, Herfarth K, Kopka K, Choyke PL, Holland-Letz T, Haberkorn U, Debus J, Giesel FL (2019)
doi: 10.2967/jnumed.118.211086
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG (2019) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer – updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. https://doi.org/10.1016/j.eururo.2019.01.049
doi: 10.1016/j.eururo.2019.01.049
Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA (2019) Assessment of
doi: 10.1001/jamaoncol.2019.0096
pubmed: 30920593
pmcid: 6567829